Incidence, prevalence, and mortality rate of gastrointestinal cancer in Isfahan, Iran: Application of the MIAMOD method by Moradpour, F. et al.
Asian Pacific Journal of Cancer Prevention, Vol 17, Cancer Control in Western Asia Special Issue, 2016 11
DOI:http://dx.doi.org/10.7314/APJCP.2016.17.S3.11 
Incidence, Prevalence, and Mortality Rate of Gastrointestinal Cancer in Isfahan, Iran
Asian Pac J Cancer Prev, 17, Cancer Control in Western Asia Special Issue, 11-15 
Introduction
Among different types of cancers, gastrointestinal 
(GI) tract cancers are the most important ones in terms of 
their broad spectrum and overall incidence. These cancers 
account for 15% of the estimated death worldwide and 
20% of the estimated new cancer cases (Herszenyi and 
Tulassay, 2010). GI system is the most common organ 
involved with more than 38% of all cancers (Sadjadi 
et al., 2005). After breast and lung cancer, colorectal, 
stomach, and liver cancers are the major ones (Global 
Burden of Disease Cancer et al., 2015). In Iran, GI 
cancers are one of the most important cancers because 
they account for more than 60 percent of deaths from 
cancer (Naghibzadeh Tahami et al., 2014). Along with 
the westernization of the lifestyle and fast economic 
development, it seems that many developing countries 
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Abstract
Gastrointestinal cancers remain the most prevalent cancers in many developing countries such as Iran. The aim of 
this study was to estimate incidence, prevalence and mortality, as well as time trends for gastrointestinal cancers in 
Isfahan province of Iran for the period 2001 to 2010 and to project these estimates to the year 2020. Estimates were 
driven by applying the MIAMOD method (a backward calculation approach using mortality and relative survival 
rates). Mortality data were obtained from the Ministry of Health and the relative survival rate for all gastrointestinal 
cancers combined was derived from the Eurocare 3 study. Results indicated that there were clear upward trends in age 
adjusted incidence (males 22.9 to 74.2 and females 14.9 to 44.2), prevalence (males 52.6 to 177.7 and females 38.3 to 
111.03), and mortality (males 14.6 to 47.2 and females 9.6 to 28.2) rates per 100,000 for the period of 2001 to 2010 
and this upward state would persist for the projected period. For the entire period, the male to female ratio increased 
slightly for all parameters (incidence rate increased from 1.5 to 1.7, prevalence from 1.4 to 1.6, and mortality from 
1.5 to 1.7). In males, totals of 2,179 incident cases, 5,097 prevalent cases and 1,398 mortality cases were predicated 
to occur during the study period. For females the predicted figures were 1,379, 3,190 and 891, respectively. It was 
concluded that the upward trend of incidence alongside increase in survival rates would induce a high burden on the 
health care infrastructure in the province of Isfahan in the future.
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RESEARCH ARTICLE
Incidence, Prevalence, and Mortality Rate of Gastrointestinal 
Cancer in Isfahan, Iran: Application of the MIAMOD Method
Farhad Moradpour1,7*, Ali Gholami
2
, Mohammad Salehi
3
, Kamiar Mansori
4
, 
Mohammad Reza Maracy
5
, Setareh Javanmardi
6
, Abdolhalim Rajabi
7
, Yousef 
Moradi
7
, Mahmod Khodadost
7,8
 
such as Iran have experienced increasing incidence rates 
of gastrointestinal cancers (Hosseini et al., 2004). Data 
collected on incidence, prevalence and cancer mortality 
are the primary resources not only for epidemiological 
research but also for quantification of the burden of the 
disease and resource allocation for planning health care 
interventions. These data can be used to extrapolate the 
trend of cancer and its variation in the future, and also 
to estimate requirements for handling the treatment 
(Jensen and Storm, 1991). Mortality data are gathered 
systematically at the national level by national organization 
for civil registration (NOFCR) in collaboration with the 
Ministry of Health (MOH) in Iran (Jafari et al., 2009). The 
data including incidence and prevalence were collected 
and analyzed by population based cancer registries 
(PBCRs) which cover only a fraction, i.e. 16%, of the 
population (Etemadi et al., 2008). However, because of 
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data processing, incidence and prevalence information are 
published with a long delay after initial data collection 
(Parkin, 2006). In this situation, when it is not possible 
to obtain accurate statistics on the cancer burden on 
regional or national level, utilization of the estimation and 
prediction methods is essential for both cancer research 
and health care prevention programs (Bray and Moller, 
2006).
The aim of this study was to estimate the incidence 
and prevalence of gastrointestinal cancers in Isfahan 
province, Iran, based on the mortality and survival data 
during 2001-2010; also, there was an attempt to predict the 
incidence, prevalence and mortality until the year 2020. 
Materials and Methods
To carry out this study, we considered all the mortality 
data and causes of mortality due to gastrointestinal cancer 
(International Classification of Disease for Oncology 3rd 
revision: code C00-C26) from two sources; NOFCR and 
MOH death registration systems. Mortality data in Iran are 
collected from Health Houses and Health Centers in the rural 
and urban areas, hospitals, forensic medicine and cemeteries 
to district health centers. In district health center, data are 
inspected by civil registration. Data are then sent to the 
provincial health center every 3-6 months and then to the 
ministry of health annually (Jafari et al., 2009). Population 
profile by age, sex and calendar year of the period 2001-
2010 were obtained from the statistics center of Iran. There 
is no study conducted to compute and estimate the relative 
survival for the digestive tract cancer in Iran. Therefore, 
we used tabulated relative survival data for the period of 
diagnosis 1983-1994 of Italian registry obtained from CD-
ROM of EUROCARE-3 study (Roazzi et al., 2003). These 
data were categorized based on the time of diagnosis to 
two year interval and following age classes of diagnosis: 
15-44, 45-54, 65-74 and 75-99 years.
The MIAMOD method (Verdecchia et al., 1989; De 
Angelis et al., 1994; Ventura et al., 2012) (Mortality 
Incidence Analysis Model) was used to derive incidence, 
prevalence and mortality statistics. It is a back calculation 
approach starting from mortality and relative survival to 
estimation and prediction of irreversible diseases such as 
cancer. Ad hoc MIAMOD/PIAMOD software developed 
by De Angelis et al (1994) was used for extracting 
estimation. This method mathematically relates the 
mortality and prevalence to a putative cancer to incidence 
and survival probabilities. Join point regression program 
was used to do a trend analysis, with the aim of observing 
whether the estimated trends are statistically significant or 
Table 1. Gastrointestinal Expected Crude Rates and Expected Cases × 100,000 by Sex and Calendar Year in Isfahan 
Province, Iran 
        Mortality       Incidence     Prevalence
                Male          female              Male            female             Male        female
Calendar 
year
0-99 
Crud rate
0-99 
cases
0-99 
Crud 
rate
0-99
 cases
0-99 
Crud 
rate
0-99
 cases
0-99 
Crud 
rate
0-99
 cases
0-99 
Crud 
rate
0-99 
cases
0-99 
Crud 
rate
0-99 
cases
2001 12.3 268.0 8.7 181.0 19.2 417.0 13.4 279.0 44.1 956.0 33.2 688.0
2002 13.1 289.0 9.2 193.0 20.5 450.0 14.2 298.0 47.2 1040.0 34.9 735.0
2003 13.9 310.0 9.7 206.0 21.7 483.0 15.0 318.0 50.4 1122.0 36.9 784.0
2004 14.9 334.0 10.2 220.0 23.2 522.0 15.8 339.0 54.2 1217.0 38.9 835.0
2005 15.9 360.0 10.8 234.0 24.8 561.0 16.7 362.0 58.0 1315.0 41.1 891.0
2006 16.9 395.0 11.4 254.0 26.4 616.0 17.6 392.0 62.0 1447.0 43.4 964.0
2007 18.0 424.0 12.1 271.0 28.0 662.0 18.7 419.0 66.0 1561.0 46.0 1031.0
2008 19.2 455.0 13.0 292.0 29.9 710.0 20.0 452.0 70.7 1677.0 49.2 1109.0
2009 20.5 488.0 13.8 312.0 31.9 760.0 21.3 482.0 75.5 1800.0 52.2 1184.0
2010 21.9 524.0 14.7 335.0 34.1 816.0 22.6 517.0 80.9 1938.0 55.6 1269.0
2011 24.1 583.0 16.2 375.0 37.5 908.0 25.0 579.0 88.6 2147.0 60.5 1398.0
2012 26.4 645.0 17.8 416.0 41.0 1004.0 27.5 643.0 96.8 2369.0 65.6 1532.0
2013 28.9 713.0 19.5 461.0 44.9 1111.0 30.1 712.0 105.7 2614.0 71.2 1682.0
2014 31.6 789.0 21.4 511.0 49.2 1227.0 33.0 788.0 115.5 2883.0 77.3 1846.0
2015 34.5 869.0 23.3 562.0 53.6 1351.0 35.8 865.0 125.8 3169.0 83.5 2018.0
2016 37.6 957.0 25.4 619.0 58.6 1491.0 39.2 956.0 137.3 3491.0 90.9 2218.0
2017 41.0 1052.0 27.6 679.0 63.9 1640.0 42.6 1051.0 149.5 3836.0 98.6 2430.0
2018 44.7 1156.0 29.9 744.0 69.7 1804.0 46.3 1153.0 163.0 4218.0 107.0 2663.0
2019 48.8 1272.0 32.5 816.0 76.0 1984.0 50.3 1263.0 177.8 4640.0 116.2 2919.0
2020 53.1 1398.0 35.2 891.0 82.8 2179.0 54.3 1378.0 193.7 5098.0 125.8 3190.0
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not. The annual variation of the rates has been measured 
by average annual percentage change (AAPC).
The incidence rate was modeled based on polynomial 
logistic model as the function of age, period and cohort 
covariate. The regression coefficients of incidence model 
were obtained by maximum likelihood method, assuming 
poison distribution of cancer mortality data (Verdecchia 
et al., 1989; De Angelis et al., 1994). Incidence was 
extrapolated to the future based on the period linear trend 
from 2001-2010, assuming that age and cohort effect do 
not change over the entire projection period. 
The entire estimate referred to the 0-99 year old age 
class. The age standardized rate was estimated based on 
the world reference population.
Results
Incidence, prevalence and mortality prediction of the 
gastrointestinal cancer until 2020 based on the period 
2001-2010 display the same increasing trend for men 
and women.  In men, there is an expected increase in 
the incidence with age standardized rate (ASR) from 
22.9 (crude rate, CR=19.2) to 74.2 (CR=82.8) cases per 
100,000 persons year (PY). The prevalence rate would 
increase from ASR 52.6 (CR=45.1) to 177.7 (193.7) and 
mortality from ASR 14.6 (CR=12.3) to 47.2 (53.1) when 
comparing the year 2001 and 2020 (Figure 1). There is 
the same incremental trend for women with respect to 
the incidence rate from ASR 14.9 (CR=13.4) to 44.2 
(CR=54.3), prevalence rate from ASR 38.3 (CR=33.2) to 
111.03 (CR=125.8) and mortality from ASR 9.6 (CR=8.7) 
to 28.2 (CR=35.2) cases per 100,000 person years (Figure 
2). Table 1 presents the estimated cases and crud rate for 
the study period by sex and calendar year. It is estimated 
that the number of dead cases will increase from 448 to 
2,289 by 2,020; incidence will increase from 696 to 3,557 
and prevalence from 1,644 to 8,287. 
Cumulative incidence risk by birth cohort was 
estimated to increase from 0.3 percent for birth cohort 
1,902 to 48 in 1999 in males and it will increase from 0.2 
to 24 percent in females (Figure 3). 
Join point regression demonstrates an average 
annual percentage change (AAPC) for aforementioned 
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figure1: Time trends of standard mortality(std.mort), incidence(std.inc) and prevalence(std.prev) estimates in 
male in Isfahan, Iran. age standardized rates (world population) per 100,000, age 0-99 years
std.mort. std.inc. std.prev.
Figure 1. Ti e Trends of Standard Mortality (std. ort), 
Incidence (std.inc) and Prevalence (std.prev) Estimates 
in Male in Isfahan, Iran. Age Standardized Rates (World 
Population) Per 100,000, Age 0-99 Years
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figure2: Time trends of standard mortality(std.mort), incidence(std.inc) and 
prevalence(std.prev) estimates in female in Isfahan, Iran. age standardized rates (world 
population) per 100,000, age 0-99 years
std.mort. std.inc. std.prev.
Figure 2. Time Trends of Standard Mortality (std.mort), 
Incidence (std.inc) and Prevalence (std.prev) Estimates 
in Female in Isfahan, Iran. Age Standardized Rates 
(World Population) Per 100,000, Age 0-99 years
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Figure 3: Estimated cumulative risk of all gasterointestinal cancer combined by birth 
cohort, age 0-74 by gender
male female
Figure 3. Estimated Cumulative Risk of All 
Gasterointestinal Cancer Combined by Birth Cohort, 
Age 0-74 by Gender
      Period                   Sex             IAAPC             (95% cl)                 PAAPC              (95% cl)                MAAPC            (95% CI)
                                    male              6.4                (6.3   6.6)                     6.8                    (6.7   6.9)                    6.4                  (6.3    6.6)
      2001-2010    
                                    female            5.9               (5.7   6.1)                    5.8                     (5.6   5.9)                    5.9                 (5.5    6.2) 
                                          male               6.3               (5.9   6.8)                    6.5                     (6.0   6.9)                    6.3                 (5.8    6.8)         2010-2020         
                                    female            5.8               (4.8   6.9)                    5.8                     (5.1   6.5)                    5.8                 (4.7    6.9)      
Table 2.  Average Annual Percentage Change of Incidence (IAAPC) Prevalence (PAAPC) and Mortality (MAAPC) of 
Gastrointestinal Cancer
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great changes in the lifestyle such as high calorie foods 
intake, lack of physical activity, smoking habits, socio 
economic factors, and population aging (Lieberman, 2003; 
Rodgers et al., 2004; Stuckler, 2008).
In 2020, there will be 3,557 new digestive cancer cases 
that need to be treated for the first time and 2289 cases will 
die, so it requires to stop medical cares. Approximately, 
15,699 patients with gastrointestinal cancer will be 
diagnosed up to 2020, and therefore, the health care system 
will be faced with a highly demanded resource. 
To conclude, our findings suggest that there is no 
reduction or leveling off in gastrointestinal cancer 
incidence in the near future. This incremental trend 
of incidence alongside the increase in the survival 
probability can induce a high burden of patient to the 
population. Finally, because of the existence of different 
types of socio-economic, behavioral and environmental 
risk factors in a different geographic area, extensive 
research is also needed to determine the cancer status at 
other regions of Iran in the future years. The authorities 
can use this information for planning heath care and 
allocating resources in public health.
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